U.S. Patent Nos. 11,612,642 and 12,257,292 protect our key drug (BBT-101) and its use in the treatment of CNS disorders, including traumatic brain injury (TBI), Parkinson's disease, Huntington's disease, stroke, depression, bi-polar disorder, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).   Beyond Barriers Therapeutics has additional patent rights pending in the U.S. and other jurisdictions.  The U.S. Food and Drug Administration (FDA) has only approved N-acetylcysteine (NAC) for the treatment of potentially hepatotoxic doses of acetaminophen.  Current intravenous formulations of NAC have been reported to be associated with the risk of serious anaphylactoid reaction, acute flushing and erythema of the skin.  Hypersensitivity reactions, including generalized urticaria have been observed in patients receiving oral NAC for acetaminophen overdose.  The risks of administering NAC intranasally are currently unknown.